Effectiveness and safety of edaravone dexborneol in acute ischemic stroke (EXPAND): Study protocol for a prospective, multicenter, real-world cohort study

依达拉奉 医学 改良兰金量表 神经保护 冲程(发动机) 前瞻性队列研究 队列 临床试验 内科学 缺血性中风 缺血 机械工程 工程类
作者
Gaoting Ma,Ran Mo,Shaoyuan Lei,Xiaoxi Yao,Zhiwei Song,Weizheng Xie,Guangxiong Yuan,Jin Hu,Yutie Zhao,Dongsheng Ju,Xiafeng Yang,Shudong Cao,Jintao Guo,Xiaodong Liu,Chunsheng Cai,Jianhua Li,Yifan Wu,Yingting Zuo,Shujuan Meng,Yue Wu
标识
DOI:10.1097/jagr.0000000000000001
摘要

Background: Edaravone dexborneol has been confirmed as a novel neuroprotective agent by acting on multiple active targets of antioxidation and anti-inflammation. Objectives: This study aims to evaluate the effectiveness and safety of edaravone dexborneol in patients with acute ischemic stroke (AIS) within 14 days of symptom onset in real-world clinical practice. Methods: This prospective, multicenter, 2-arm, parallel, real-world cohort study will involve 72 stroke centers in China and plans to recruit 4750 exposed/unexposed patients with a 2:1 ratio to gather additional safety information on edaravone dexborneol. Patients eligible of the Effectiveness and Safety of Edaravone Dexborneol in Acute Ischemic Stroke (EXPAND) are diagnosed with AIS within 14 days of symptom onset. The eligible patients who receive edaravone dexborneol will be assigned to the exposed group, while those without using edaravone dexborneol will be assigned to the unexposed group. All participants will be followed up for 90 days. The primary outcome is a favorable functional outcome as defined by a modified Rankin Scale (mRS) score 0–1 at 90 days. Primary efficacy in the 2 groups will be compared using multivariable logistic regression. Results: EXPAND is the first real-world study to elucidate the efficacy and safety of edaravone dexbornel in AIS, which has the potential to extend the therapeutic time window of neuroprotective treatment and propose a multiple-target approach for AIS. Conclusions: The protocol was approved by the Ethics Committee at all participating sites [the reference number of central ethic committee: (2022)090] and by the local Institutional Review Board of each participating center. The findings of the study will be published in peer-reviewed scientific journals and presented at national and international conferences. This cohort study only collects real-world patient data during the diagnosis and treatment process. The refusal of a patient to participate or the decision to withdraw from the study will not interfere with the clinical decision-making. Thus, no additional risk will be imposed. Trial registration number: NCT05644223.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
不灭的灯完成签到,获得积分10
1秒前
1秒前
风1发布了新的文献求助10
1秒前
pluto的应助被彩色白秋采纳,获得50
1秒前
nidiedeer发布了新的文献求助10
1秒前
岳雨萌发布了新的文献求助10
2秒前
wangyu3完成签到,获得积分10
3秒前
5秒前
5秒前
jar7989发布了新的文献求助10
5秒前
夜里看文献完成签到 ,获得积分10
6秒前
www完成签到 ,获得积分10
6秒前
yuanyuan完成签到,获得积分10
6秒前
Xwr完成签到,获得积分20
6秒前
在水一方的应助被kuridan采纳,获得10
6秒前
ylf完成签到,获得积分10
6秒前
法国v刚刚发布了新的文献求助10
7秒前
上官若男的应助被zxqzxq采纳,获得10
7秒前
娇娇老师完成签到,获得积分10
7秒前
ff发布了新的文献求助10
7秒前
魏伯安发布了新的文献求助10
8秒前
8秒前
小xy发布了新的文献求助10
9秒前
Maestro_S的应助被Zilean采纳,获得10
9秒前
9秒前
10秒前
韩han发布了新的文献求助10
10秒前
10秒前
nidiedeer完成签到,获得积分10
11秒前
美丽的向雁完成签到,获得积分10
11秒前
研友_VZG7GZ的应助被胡萝卜卜采纳,获得10
11秒前
昏睡的凡松完成签到 ,获得积分10
11秒前
11秒前
叶艳完成签到 ,获得积分10
12秒前
拼搏曲奇完成签到,获得积分10
13秒前
姜太公发布了新的文献求助10
14秒前
14秒前
14秒前
大酱踢腿发布了新的文献求助10
14秒前
shocwk发布了新的文献求助10
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8191314
求助须知:如何正确求助?哪些是违规求助? 9578210
关于积分的说明 21857267
捐赠科研通 7790624
什么是DOI,文献DOI怎么找? 3436606
关于科研通互助平台的介绍 2560359
邀请新用户注册赠送积分活动 2483305